About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
W
Polatuzumab Vedotin for 1L DLBCL: Results From the POLARIX Trial
By
Wojciech Jurczak
4 Videos
175 views
June 26, 2024
1 Comment
Login to view comments.
Click here to Login
Featured Video
24:44
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignan…
Feat.
R. Birhiray
Featured Video
24:35
Indy Hematology Review
Current Approaches in the Treatment of Myeloproliferative Neoplasms
Feat.
A. Tefferi
Related Content
AUTOPLAY
ON
21:05
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
Feat.
R. Gale
22:09
Scripps Health
New Updates in Frontline DLBCL
Feat.
L. Nastoupil
27:47
Indy Hematology Review
Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…
Feat.
S. Smith
10:04
Tara Graff
How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…
35:27
Louisville Hematology Highlights
Updates on Management of DLBCL
Feat.
J. Leonard
62:02
UChicago Medicine
New Treatment Strategies in DLBCL
Feat.
L. Sehn
35:24
SOHO Highlights: State of the Art and Next Questions
State of the Art and Next Questions: Aggressive B-Cell Lymphomas
Feat.
G. Nowakowski
17:21
Daniel Addison
Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…
33:48
SOHO Highlights: State of the Art and Next Questions
State of the Art and Next Questions: B-Cell Lymphoma
Feat.
L. Nastoupil
15:33
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Has R-CHOP Really Been Replaced as Initial Therapy of DLB…
Feat.
J. Friedberg
34:36
MyCancerHaven
Frontline DLBCL Treatment Approaches
Feat.
R. Vij,
H. Cherng
06:09
Insights from 2023 ASH Annual Meeting
CLL/SLL: Outcomes of Pts With Richter's Transformation Without …
Feat.
A. Kittai
25:44
Tara Graff
DLBCL Updates From iCML 2023
08:01
Georg Lenz
Treatment Landscape in 1L DLBCL: Polatuzumab Vedotin as SoC
29:26
Massachusetts General Hospital Cancer Center
Practice-Changing Updates in DLBCL and HL
Feat.
J. Erika Haydu
17:11
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: Incorporating Novel Agents in Frontline DLBCL
Feat.
L. Sehn
35:28
UNC Lineberger Comprehensive Cancer Center
DLBCL Management: Updates for 2023
Feat.
N. Grover
26:58
Total Health
Update on Cellular Therapy in Lymphoma
Feat.
B. Randolph
16:39
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
2024 Targeted Therapy Updates for Aggressive B-Cell Lymphomas
Feat.
D. Landsburg
17:51
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies
Chronic GVHD: A Case-Based Discussion
Feat.
L. Perry
